SCHEMBL4603375

SCHEMBL4603375

COC(=O)c1ccc2c(C(=O)c3c(-c4ccc(F)cc4)noc3C)c[nH]c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 1/20 0.47
LMNA P02545 2/20 0.47
GABRA5 P31644 3/20 0.46
NPC1 O15118 1/20 0.43
NR4A2 P43354 2/20 0.42
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 2/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
PARP1 P09874 1/20 0.41
GPBAR1 Q8TDU6 1/20 0.40
MAPT P10636 1/20 0.39
RECQL P46063 1/20 0.39
GAA P10253 2/20 0.39
TSHR P16473 2/20 0.39
ASH1L Q9NR48 1/20 0.39
MAPK13 O15264 1/20 0.39
ALOX5 P09917 1/20 0.39
GCGR P47871 1/20 0.39
MAPK12 P53778 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4606874 0.90 ALDH1A1 (0.51) LMNAGABRA5NPC1ALDH1A1KDM4E
SCHEMBL4605621 0.90 GABRA5 (0.50) MAP2K4GABRA5NPC1NR4A2ALDH1A1
SCHEMBL4605376 0.89 ALDH1A1 (0.43) MAP2K4LMNAGABRA5NR4A2ALDH1A1
SCHEMBL4605464 0.85 GABRA5 (0.50) LMNAGABRA5ALDH1A1KDM4EKMT2A
SCHEMBL14188857 0.85 CYP1A2 (0.45) LMNAGABRA5ALDH1A1KDM4EKMT2A
SCHEMBL4604077 0.84 CYP1A2 (0.40) LMNAGABRA5ALDH1A1KDM4EKMT2A
SCHEMBL4606782 0.83 GABRA5 (0.48) LMNAGABRA5NPC1ALDH1A1KDM4E
SCHEMBL4606350 0.83 GABRA5 (0.48) LMNAGABRA5NPC1ALDH1A1KDM4E
SCHEMBL27718425 0.83 TUBB1 (0.42) LMNAKDM4EGPBAR1MAPTRECQL
SCHEMBL4604378 0.83 GABRA5 (0.53) LMNAGABRA5ALDH1A1KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1937674-A1 ISOXAZOLE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-07-02 EP disclosed
US-7378435-B2 Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives HOFFMANN-LA ROCHE INC. (US) 2008-05-27 US disclosed
WO-2007042420-A1 ISOXAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-04-19 WO disclosed
US-20070082936-A1 Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives HOFFMANN-LA ROCHE INC. 2007-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070082936-A1 Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives GABRA5, GABRA4, CHRNA5 MAP2K4 3769/4885LMNA 3387/4885GABRA5 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.